Retifanlimab
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Penile Cancer
Conditions
Penile Cancer
Trial Timeline
Apr 28, 2020 → Aug 26, 2022
NCT ID
NCT04231981About Retifanlimab
Retifanlimab is a phase 2 stage product being developed by Incyte for Penile Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04231981. Target conditions include Penile Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06910137 | Pre-clinical | Active |
| NCT04231981 | Phase 2 | Completed |
| NCT03599713 | Phase 2 | Completed |
| NCT03679767 | Phase 2 | Completed |
| NCT03597295 | Phase 2 | Completed |
| NCT03059823 | Phase 1 | Completed |
Competing Products
8 competing products in Penile Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avelumab + enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Standard of care therapy | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab | Roche | Phase 2 | 52 |
| Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires | Pfizer | Pre-clinical | 22 |
| Dacomitinib | Pfizer | Phase 2 | 51 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |